Page last updated: 2024-09-04

docetaxel anhydrous and clopidogrel

docetaxel anhydrous has been researched along with clopidogrel in 3 studies

Compound Research Comparison

Studies (docetaxel anhydrous)	Trials (docetaxel anhydrous)	Recent Studies (post-2010) (docetaxel anhydrous)	Studies (clopidogrel)	Trials (clopidogrel)	Recent Studies (post-2010) (clopidogrel)
12,110	3,216	6,920	10,221	1,918	5,951

Protein Interaction Comparison

Protein	Taxonomy	docetaxel anhydrous (IC50)	clopidogrel (IC50)
Sodium-dependent serotonin transporter	Homo sapiens (human)		0.562
P2Y purinoceptor 12	Homo sapiens (human)		2.4

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
De Rosa, G; Napodano, M; Padrini, R; Pengo, V; Plebani, M; Silvano, M; Zambon, CF	1
Jang, YP; Kim, HJ; Lee, JH; Lee, YJ; Oh, JH; Shin, YJ	1

Reviews

1 review(s) available for docetaxel anhydrous and clopidogrel

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

2 other study(ies) available for docetaxel anhydrous and clopidogrel

Article	Year
A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty. Journal of thrombosis and thrombolysis, 2011, Volume: 31, Issue:2 Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents; Clopidogrel; Docetaxel; Drug Resistance; Drug-Eluting Stents; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Taxoids; Thiophenes; Thrombosis; Ticlopidine	2011
Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions. International journal of pharmaceutics, 2011, May-30, Volume: 410, Issue:1-2 Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cyclosporine; Cytochrome P-450 CYP3A; Docetaxel; Drugs, Chinese Herbal; Herb-Drug Interactions; Infusions, Intravenous; Male; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Salvia miltiorrhiza; Taxoids; Ticlopidine	2011

Article

Year

A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty.

Journal of thrombosis and thrombolysis, 2011, Volume: 31, Issue:2

Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents; Clopidogrel; Docetaxel; Drug Resistance; Drug-Eluting Stents; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Taxoids; Thiophenes; Thrombosis; Ticlopidine

2011

Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions.

International journal of pharmaceutics, 2011, May-30, Volume: 410, Issue:1-2

Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cyclosporine; Cytochrome P-450 CYP3A; Docetaxel; Drugs, Chinese Herbal; Herb-Drug Interactions; Infusions, Intravenous; Male; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Salvia miltiorrhiza; Taxoids; Ticlopidine

2011